Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs

Anticancer Research

Volumn 18, Issue 4 C, 1998, Pages 2937-2944

  Aszalos, A ^a   Ross, D D ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; MRP; Multidrug resistance; P glycoprotein; Resistance modulators

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN;

BIOCHEMISTRY; CANCER RESISTANCE; CLINICAL FEATURE; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0031839225     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporters. Ann Rev Biochem 62: 385-427, 1993
2. Chen Cj, Chin JE, Ueda K, Clark D, Pastan I, Gottesman MM, Roninson I: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381-389, 1986
3. Lomri N, Fitz JG, Scharschmidt BF: Hepatocellular transport: role of ATP-binding cassette proteins. Semin Liver Dis 16: 201-210, 1996.
4. Higgins CF: The ABC transport channel superfamily - an overview. Semin. Cell Biol 4: 1-5, 1993.
5. Weaver JL, McKinney L, Schoenlein PV, Goldenberg S, Gottesman MM, Aszalos A: MDR1/P-glycoprotein in function I. Effect of hypotonicity and inhibitors on rhodamine 123 exclusion. Am J Physiol 270: C1447-C1452, 1996.
6. Ueda K, Cardarelli C, Gottesman MM, Pastan I: Expression of a full-length cDNA for the human "MDR" gene confers resistance to colchicine, doxorubicine and vinblastine. Proc Natl Acad Sci 84: 3004-3008, 1987.
7. Choi K, Chen Cj, Kriegler M, Roninson IB: An altered pattern of cross-resistance in multidrug resistant human cells results from spontaneous mutation in the mdr-1 (P-glycoprotein) gene. Cell 53: 519-528, 1989.
8. Sorrentino BP, Brandt SJ, Bodine D, Gottesman MM, Pastan I: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257: 99-107, 1992.
9. Ganapathi R, Hoeltge G, Casey G, Grabowski D, Neelon R, Ford J: Acquisition of doxo-rubicin resistance in human leukemia HL-60 cells is reproducibly associated with 7p21 chromosomal anomalies. Cancer Genet Cytogenet 86: 116-119, 1996.
10. Chin KV, Ueda K, Pastan I, Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459-461, 1992.
11. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komaro T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267: 24248-24252, 1992.
12. Schinkel AH, Wagenaar E, Mol CA, van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517-2524, 1996.
13. Currier SJ, Ueda K, Willingham MC, Pastan I, Gottesman MM: Detection and insertion mutants of the multidrug transporter. J Biol Chem 264: 14376-14381, 1989.
14. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE: Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute Drug screen. Mol Pharmacol 46: 627-638, 1994.
15. Weaver JL, Pine SP, Aszalos A, Schoenlein PV, Currier SJ, Padmanabhan R, Gottesman MM: Laser scanning and confocal microscopy of daunorubicin and rhodamine 123 in multidrug resistant cells. Exper Cell Res 196: 323-329, 1991.
16. Aszalos A, Pine PS, Pandey R, Gottesman MM: Behavior of N-acylated daunorubicins in MDR1 gene transfected and parental cells. Biochem Pharmacol 50: 889-892, 1995.
17. Jette L, Beaulieu E, Leclerc JM, Beliveau R: Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 270: F756-F765, 1996.
18. Dumontet C, Duran GE, Steger KA, Chen G, Sikic BI: Resistance to modulation of multidrug resistance (MDR) selected by concurrent exposure to PSC833 (PSC), doxorubicin and vincristine. Proc Am Assoc Cancer Res 37: 329, 1996.
19. Lan LB, Ayesh S, Lyubimov E, Pashinsky I, Stein WD: Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing. Cancer Chemother Pharmacol 38: 181-190, 1996.
20. Hwang M, Ahn CH, Pine PS, Yin JJ, Hrycyna CA, Licht T, Aszalos A: Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells. Int J Cancer 65: 389-397, 1996.
21. Wadkins RM, Houghton PJ: The role of drug-lipid interactions in the biological activity of modulators of multidrug resistance. Biochem. Biophy Acta 1153: 225-236, 1993.
22. Scala, S, Akhmed N, Rao US, Paull K, Lan LB, Dickstein B, Lee JS, Elgemeie GH, Stein WD, Bates SU: P-glycoprotein substrates and antagonists cluster into two distinct groups. Molec Pharmacol 51: 1024-1033, 1997.
23. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357-361, 1994.
24. Kruh GD, Gaughan KT, Godwin A, Chan A: Expression pattern of MRP in human tissues and adult solid tumor cell lines. J Natl Cancer Inst 87: 1256-1258, 1995.
25. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
26. Stride BD, Valdimarsson G, Gerlach JH, Cole SPC, Deeley RG: Structure and expression of messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter. Mol Pharmacol 49: 962-971, 1996.
27. Dauwerse JG, Jumelet EA, Wessels JW, Saris JJ, Hagemeier A, Beverstock GC, VanOmmen GJB, Breuning MH: Extensive cross-homology between the long and the short arm of chromosome 16 may explain leukemic inversion and translocations. Blood 79: 1299-1304, 1992.
28. Eijdems EW, De-Haas M, Coco-Martin JM, Ottenheim CP, Zaman GJ, Dauwerse HG, Breuning MH, Twentyman PR, Borst P, Baas F: Mechanism of MRP overexpression in four human lung cancer cell lines and analysis of the MRP amplicon. Int J Cancer 60: 676-684, 1995.
29. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D: Transport of glutathione, glucuronate and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56: 988-994, 1996.
30. Feller N, Kuiper CM, Lankelma J, Ruhdal JK, Scheper RJ, Pinedo HM, Broxterman HJ: Functional detection of MDR1/P170 and MRP/P190 mediated multidrug resistance in tumor cells by flow cytometer. Br J Cancer 72: 543-549, 1995.
31. Doyle LA, Ross DD, Ordonez JV, Yang W, Gao Y, Tong Y, Belani CP, Gutheil JC: An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein. Br J Cancer 72: 535-542, 1995.
32. Paul S, Breuninger LA, Tew KD, Shen H, Kruh GD: ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. Proc Natl Acad Sci 93: 6929-6934, 1996.
33. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen THM, van Kalken CK, Slovak ML, de Vries EGE, van der Valk P, Meijer CJLM, Pinedo HM: Overexpression of a Mf 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475-1479, 1993.
34. Slovak LS, Ho JP, Cole SPC, Deeley RG, Greenberger L, de Vries EGE, Broxterman HJ, Scheffer GL, Scheper RJ: The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 55: 4214-4219, 1995.
35. Schuurhuis GJ, Broxterman HJ, de Lange JHM, Pinedo HM, van Heijningen THM, Kuiper CM, Scheffer GL, Scheper RJ, van Kalken CK, Baak JPA, Lankelma J: Early multidrug resistance, defined by changes in intracellular doxorubicine distribution, independent of P-glycoprotein. Br J Cancer 64: 857-861, 1991.
36. List AF: Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 10: 937-942, 1996.
37. Murren JR, DeVita VG Jr: Another look at multidrug resistance. PPO updates 9: 1-12, 1995.
38. Fisher GA, Sikic BI: Clinical studieswithmodulators of multidrug resistance. In: Drug Resistance in Clinical Oncology and Hematology, Hematol Clin of N America 9: 363-382, 1995.
39. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP: Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemo-sensitizer. Blood 78: 44-50, 1991.
40. Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM Herdt J et al: Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13: 1995-2004, 1995.
41. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futcher B, Baier M, Dalton W: Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11: 1652-1660, 1993.
42. - cases. Blood 86: 2329-2342, 1995.
43. Schuurhuis J, Broxterman HJ, Ossenkoppele GJ, Baak JP, Eekman CA, Kuiper E, Pieters R, et al: Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosyl cytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1: 81-93, 1995.
44. Ross DD, Doyle LA, Schiffer CA, Lee EJ, Grant CE, Cole SPC, Deeley RG, Yang W, and Tong, Y: Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. Leukemia 10: 48-55, 1996.
45. Lee SJ, Scala S, Matsumoto Y, Dickstein B, Robey R, Zhan Z, Altenberg G, and Bates SE: Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cellular Biochem 65: 513-526, 1997.
46. Doyle LA, Ross DD, Sridhara R, Fojo AT, Kaufinann SH, Lee EJ, Schiffer CA: Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells. Br J Cancer 71: 52-58, 1995.
47. Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Roe DJ, Trent JM: Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF-7 human breast cancer cell line. Br J Cancer 63: 923-926, 1991.
48. Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, Morrow C, Cowan KH. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 52: 6175-6181, 1992.